je.st
news
Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based...
2013-11-02 15:57:50| Biotech - Topix.net
Gilead Sciences, Inc. today announced results from a Phase 3 study, PHOTON-1, evaluating the investigational once-daily nucleotide analogue sofosbuvir for the treatment of chronic hepatitis C virus infection among patients co-infected with HIV.
Tags: results
phase
announces
gilead
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||